Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03365778 · ClinicalTrials.gov registry record · NA
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT03365778: Completed NA study, sponsored by Wills Eye.
NCT03365778 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 86 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03365778, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.
Primary Outcome
Percentage of patients who elect the Selective Laser Trabeculoplasty (SLT), as treatment for lowering eye pressure, compared between a group receiving SLT Educational Intervention and a Usual Care group. Follow-up eye examinations will be screened for a 6-month period to assess number of completed SLTs.
Interventions
- OTHER Usual Care
- OTHER Patient Educational Intervention
- OTHER Ophthalmologist Educational Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT03365778 record still lists
NCT03365778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Usual Care is the first listed.
NCT03365778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03365778 about?
NCT03365778 is a clinical study titled "Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment". The purpose of this study is to develop an educational program that will help improve the patients' understanding of what laser treatment is, how it might be beneficial to them, and why it should be the first eye pressure lowering glaucoma treatment to consider before the use of glaucoma eye drops.
What is the current status of trial NCT03365778?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2017-10-23. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03365778?
The interventions under investigation include: Usual Care (OTHER), Patient Educational Intervention (OTHER), Ophthalmologist Educational Intervention (OTHER).
Who is sponsoring clinical trial NCT03365778?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03365778's enrollment target sits among peer trials
86 976th of 2000 higher than 1,021 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI